Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02133742 · ClinicalTrials.gov registry record · Phase 1
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT02133742 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 52 participants.
The verdict
NCT02133742, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
Despite substantial improvements of patients outcome in advanced RCC, durable and complete response is uncommon. The majority of patients eventually develop resistance and exhibit disease progression. Combining a PD-1 inhibitor, which has shown single-agent efficacy with axitinib may provide additional clinical benefit compared to axitinib alone.
Interventions
- DRUG Axitinib
- DRUG MK-3475
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2014-09-16 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02133742
The ClinicalTrials.gov registry entry for NCT02133742 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Axitinib is the first listed.
NCT02133742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02133742 about?
NCT02133742 is a clinical study titled "A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer". Despite substantial improvements of patients outcome in advanced RCC, durable and complete response is uncommon. The majority of patients eventually develop resistance and exhibit disease progression. Combining a PD-1 inhibitor, which has shown single-agent efficacy with axitinib may provide additio...
What is the current status of trial NCT02133742?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2014-09-16. Estimated completion is 2019-07-03.
What interventions are being tested in trial NCT02133742?
The interventions under investigation include: Axitinib (DRUG), MK-3475 (DRUG).
Who is sponsoring clinical trial NCT02133742?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.